Hoth Therapeutics Inc

Hoth Therapeutics Inc operates with a market capitalization of $13.98 million and a price-to-book ratio of 2.27, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by a current ratio of 4.72, suggesting strong short-term liquidity, with no long-term debt and total liabilities of $1.45 million against total assets of $7.60 million. The company's equity base of $6.15 million supports this liquidity, but its operating cash flow of -$9.80 million indicates ongoing cash burn. Profitability metrics show a challenging financial position, with a return on equity of -2.03% and a return on assets of -1.64%, both significantly below the industry median for pharmaceutical companies. The company reported a net loss of $12.47 million and an operating loss of $12.36 million in the latest period, reflecting the high costs associated with drug development and regulatory compliance. The company's revenue is not disclosed in the latest financials, and its business is not segmented by geography or product line in the available data. This lack of segmentation makes it difficult to assess geographic or product concentration risks, but the absence of disclosed revenue suggests the company is in an early development or clinical trial phase. Looking ahead, the company's growth trajectory is uncertain, with no disclosed revenue and a negative earnings per share of -$0.90 in the latest period. The company's capital expenditures of -$300,000 suggest limited investment in physical assets, which is typical for a biopharmaceutical firm focused on R&D rather than manufacturing. The absence of dilution flags and the low dilution risk suggest that the company is not currently issuing new shares to raise capital. Recent filings and transcripts do not provide additional insight into the company's operations or strategic direction, as the latest actual revenue is reported as $0.00. This may indicate that the company is in the early stages of commercialization or has not yet launched a product to market.